854472-87-0

Basic information

• Product Name: methyl 2,3-dimethoxy-5-[(4-methylphenyl)sulfonyl]benzoate
• Synonyms: methyl 2,3-dimethoxy-5-[(4-methylphenyl)sulfonyl]benzoate
• CAS NO: 854472-87-0
• Molecular Weight: 350.392
• Mol File: 854472-87-0.mol

Chemical Properties

• CAS DataBase Reference: methyl 2,3-dimethoxy-5-[(4-methylphenyl)sulfonyl]benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,3-dimethoxy-5-[(4-methylphenyl)sulfonyl]benzoate(854472-87-0)
• EPA Substance Registry System: methyl 2,3-dimethoxy-5-[(4-methylphenyl)sulfonyl]benzoate(854472-87-0)

Safety Data

• Hazardous Substances Data: 854472-87-0(Hazardous Substances Data)

Upstream product

• 824-79-3 sodium 4-methylbenzenesulfinate 
• 171805-85-9 methyl 5-iodo-2,3-dimethoxybenzoate 

Downstream Products

• 854472-92-7 9-{(E)-7-[({2,2-bis(4-methoxyphenyl)-6-[(4-methylphenyl)sulfonyl]-1,3-benzodioxol-4-yl}carbonyl)amino]-5,6,7-trideoxy-2,3-O-(1-methylethylidene)-β-D-ribo-hept-5-enofuranosyl}-9H-purin-6-amine 
• 854472-91-6 2,2-bis(4-methoxyphenyl)-6-[(4-methylphenyl)sulfonyl]-1,3-benzodioxole-4-carboxylic acid 
• 854472-90-5 methyl 2,2-bis(4-methoxyphenyl)-6-[(4-methylphenyl)sulfonyl]-1,3-benzodioxole-4-carboxylate 
• 854472-89-2 methyl 2,3-dihydroxy-5-[(4-methylphenyl)sulfonyl]benzoate 
• 854472-88-1 2,3-dihydroxy-5-[(4-methylphenyl)sulfonyl]benzoic acid 

Relevant articles and documents

Synthesis and biological evaluation of potent bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT) lacking a nitro group

Inhibition of the enzyme catechol O-methyltransferase (COMT) represents a viable strategy for regulation of the catabolism of catecholamine neurotransmitters or their precursors, and is of considerable interest in the therapy of Parkinson's, disease. Here

New COMT inhibitors for the treatment of depression and impaired cognition

The present invention relates to compounds of formula I wherein R1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or prevention of diseases such as depression, schizophrenia, Parkinson's disease, and to improve cognition.